FMTX - Forma Therapeutics reports positive FT-4202 data in sickle cell disease

Forma Therapeutics (FMTX) announces new data from its ongoing Phase 1 trial of FT-4202 in patients with sickle cell disease ((SCD)).The new findings include data analysis from the second cohort of patients receiving 600 mg of FT-4202 or placebo once daily for 14 days and a 7-day follow up period.Aggregate findings demonstrated 10 of 14 patients (71%) who received FT-4202 achieved a hemoglobin increase of ?1 g/dL from baseline with once-daily dosing of FT-4202 during 14 days of treatment.The data also showed activation of pyruvate kinase-R ((PKR)) by FT-4202 increased sickle RBC survival and reduced intravascular hemolysis in patients with SCD based on a reduction in reticulocytes, bilirubin and LDH levels. “We are excited to see the favorable safety and tolerability profile of FT-4202 at a 600 mg dose, coupled with the overlap of pharmacodynamic activity and biologic effects across the 300 and 600 mg doses, supporting the evaluation of safety and

For further details see:

Forma Therapeutics reports positive FT-4202 data in sickle cell disease